NR APCF
AU Bader,F.; Davis,G.; Dinowitz,M.; Garfinkle,B.; Harvey,J.; Kozak,R.; Lubiniecki,A.; Rubino,M.; Schubert,D.; Wiebe,M.; Woollett,G.
TI Assessment of risk of bovine spongiform encephalopathy in pharmaceutical products part - 2 - example risk assessment for a hypothetical product
QU Biopharm - The Technology & Business of Biopharmaceuticals 1998; 11(N3): 18
PT Article
AB Part 2 of this two-part article concludes PhRMA's current guideline for conducting BSE risk assessment by providing a case study for assessing risk on a hypothetical product called Curex.
ZR 15 Zitate
SP englisch